Investigating immunotherapies for endometrial cancer: Working as a MDT to identify patients and improve outcomes
Select a discussion in the hub to watch our multidisciplinary faculty share their expert perspectives on the potential of immunotherapies to improve the management of patients with endometrial cancer.
- Evaluate the latest data for PD-1/PD-L1 inhibitors in the treatment of endometrial cancer
- Identify which patients with EC may benefit from treatment with PD-1 inhibitors
- Summarize the appropriate testing used to assess whether PD-1 inhibitors maybe suitable for patients with EC
Managing adverse events associated with BCMA-targeting agents in multiple myeloma: The role of the multidisciplinary team
Watch leading experts review adverse event management with BCMA-targeting multiple myeloma therapies, and consider the role of the multidisciplinary team.
- Use the most appropriate management strategy for patients experiencing ocular toxicity following treatment with a BCMA-targeting antibody-drug conjugate
- Discuss the adverse events associated with BCMA-targeting CAR T-cell therapies, and how they can be managed
- Recognize the importance of the multidisciplinary care team in the management of patients receiving a BCMA-targeting therapy for multiple myeloma
Brian Van Tine, ASCO 2021: Findings from the APROMISS Study
We were delighted to talk with Dr Brian Van Tine (Washington University School of Medicine, Saint Louis, MO, US) around the APROMISS study, investigating the efficacy and safety of AL3818 hydrochloride monotherapy in patients with metastatic or advanced synovial sarcoma. The abstract ‘A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects […]
Evan Lipson, ASCO 2021: Relatlimab plus Nivolumab in Advanced Melanoma
TouchONCOLOGY got the chance to catch up with Dr Evan Lipson (Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA) around the RELATIVITY-047 study, which investigated the combined therapy of relatlimab plus nivolumab in patients with advanced melanoma. The abstract ‘Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III […]
Sara Tolaney, ASCO 2021: Abemaciclib in HR+, HER2+ high-risk early breast cancer
touchONCOLOGY joins Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss unmet needs and ongoing research in patients with early-stage HER2+ breast cancer. The abstract ‘eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer […]
Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma
Oncology & Hematology Review. 2020;16(2):90–4 DOI: https://doi.org/10.17925/OHR.2021.16.2.90
Esophageal cancer is the seventh most common malignancy and the sixth leading cause of death from cancer worldwide.1 The main histological subtypes are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. ESCC is the most common subtype, and the frequency of this disease is highest in Eastern Asia and Eastern Africa.2 In Western countries, however, the incidence […]
Latest Developments in Cellular Therapy for Multiple Myeloma
Oncology & Hematology Review (US). 2020;16(2):111-8 DOI: https://doi.org/10.17925/OHR.2021.16.2.111
Multiple myeloma (MM) is a malignant clonal disorder of plasma cells in the bone marrow, and more than 32,000 new cases are expected in the USA each year.1 Many clinical advances, including novel drugs and continuous therapy with treatment sequencing, have improved survival statistics.2 Despite this, MM remains largely incurable and the relapsed/refractory population remains vulnerable […]
Pexidartinib and CSF1R Inhibitors as Treatment for Tenosynovial Giant Cell Tumors
Oncology & Hematology Review (US). 2020;16(2):119-23 DOI: https://doi.org/10.17925/OHR.2021.16.2.119
Tenosynovial giant cell tumor (TGCT)—previously referred to as giant cell tumor of the tendon sheath or pigmented villonodular synovitis (PVNS)—is a largely benign, rare, proliferative lesion arising from the synovial lining of joints, bursae, and tendon sheaths.1 This review serves to discuss the epidemiology, molecular biology, clinical behavior, and the current treatment modalities of TGCT that […]
Evolving Therapies for Urothelial Carcinoma—Novel Paradigms and Future Directions
Oncology & Hematology Review. 2020;16(2):82-9 DOI: https://doi.org/10.17925/OHR.2021.16.2.82
Urothelial carcinoma is the most common histologic type of bladder cancer in the USA and Europe, accounting for 90% of all bladder cancers. It is the sixth most common type of cancer diagnosed in the USA, and the 10th leading cause of cancer death, with an estimated 17,980 deaths predicted in 2020.1 Although the 5-year survival […]
Continually improving care: Evolving role of the MDT in early EGFR-mutant NSCLC
Watch leading specialists from the multidisciplinary tumour board discuss optimal approaches to managing patients with early-stage NSCLC, with or without an EGFR driver mutation
Optimizing the management of gastroenteropancreatic neuroendocrine tumours
Watch leading experts explore how recent scientific and clinical advances may optimize the medical management of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in 2021, and beyond.
Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer
touchREVIEWS in Oncology & Haematology. 2021;17(1):12-7 DOI: https://doi.org/10.17925/OHR.2021.17.1.12
The metastatic setting has traditionally been the initial venue for the development of new drugs in breast cancer. This seems like a natural population in which to start because patients have often exhausted the armamentarium of approved agents and, therefore, clinical equipoise is easier to achieve. These trials, however, often involve sicker patients who can […]
Foreword – touchREVIEWS in Oncology & Haematology – VOLUME 17 ISSUE 1 – 2021
touchREVIEWS in Oncology & Haematology. 2021;17(1):1-2
Welcome to the inaugral issue of touchREVIEWS in Oncology & Haematology (formerly Oncology & Hematology Review [US]), which aims to summarize the latest clinical data and provide practical advice to help busy physicians in their daily practice. As co-editors-in-chief of this new title, we are excited to bring you a range of interesting and informative […]
High-risk Endometrial Cancer: The Present and Future of Adjuvant Therapy
touchREVIEWS in Oncology & Haematology. 2021;17(1):23-27 DOI: https://doi.org/10.17925/OHR.2021.17.1.23
Endometrial cancer has become an increasingly significant cause of morbidity and mortality for women. Currently, endometrial cancer is the most common invasive gynaecologic malignancy, and the ninth most common cancer among women in the USA, accounting for approximately 65,620 new cancer cases and 12,590 deaths in 2020.1 The 5-year relative survival rate is estimated to be […]
Advanced and Metastatic Gastrointestinal Stromal Tumours: Review of Current Knowledge and Latest Advances
touchREVIEWS in Oncology & Haematology. 2021;17(1):18-22 DOI: https://doi.org/10.17925/OHR.2021.17.1.18
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal (GI) tract, accounting for 0.1–3.0% of all GI malignancies, and 80% of all GI sarcomas.1–5 While GISTs can occur throughout the entire GI tract, with similar male/female incidence, 60% of cases usually present in the stomach, and about 30% in the small […]
Want To Know More About Our Journals?
Taking a balanced and practical view of the current clinical landscape in Oncology is at the heart of touchONCOLOGY and the journals we produce.
The European Oncology & Haematology and Oncology & Hematology Review (US) are free-to-access, peer reviewed journals that aim to provide balanced and objective articles relevant to the day-to-day clinical setting.
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!